MannKind Corporation received a grant from Breakthrough T1D to support the INHALE-1ST trial, which tests the safety and effectiveness of Afrezza, an inhaled insulin, in children aged 10 to under 18 newly diagnosed with type 1 diabetes. This trial follows recent FDA approval of Afrezza for pediatric use and aims to improve diabetes management by offering a rapid-acting, inhaled insulin option alongside basal insulin. The study will track glucose control and user satisfaction over 13 weeks, potentially transforming pediatric diabetes care by reducing treatment burden. MannKind's collaboration with Breakthrough T1D highlights growing confidence in inhaled insulin's role in early diabetes treatment for youth.
The global reactive hot melt adhesives market is projected to grow from $2.02 billion in 2025 to $4.29 billion by 2035, at a CAGR of 7.72%. Growth is driven by regulations limiting solvent-based adhesives, increased use of polyurethane adhesives in a...
The global automotive microcontrollers market is projected to grow from USD 15.49 billion in 2025 to USD 34.31 billion by 2035, at a CAGR of 8.28%. Growth is fueled by increasing adoption of advanced driver-assistance systems (ADAS), vehicle electrif...
CHARBONE Corporation has increased its helium delivery fleet from one to five units to meet rising demand caused by global helium supply disruptions, notably from Qatar. This expansion supports North American customers in sectors like semiconductors ...
Citi has started coverage of Hikma Pharmaceuticals with a 'buy' rating and a £17 price target, highlighting the company's strategic shift towards differentiated products and US manufacturing investments. The broker sees a 14% potential share price re...
Xenon Pharmaceuticals is evolving into a late-stage, cash-rich neuroscience company with a validated Kv7 potassium channel platform. Its lead drug candidate, azetukalner, has shown strong effectiveness in treating refractory focal onset seizures and ...
